Suppr超能文献

他莫昔芬耐药乳腺癌细胞中多药耐药相关蛋白2的诱导

Induction of multidrug resistance associated protein 2 in tamoxifen-resistant breast cancer cells.

作者信息

Choi Hoo Kyun, Yang Jin Won, Roh Sang Hee, Han Chang Yeob, Kang Keon Wook

机构信息

BK21 Project Team, College of Pharmacy, Chosun University, 375 Seosuk-dong, Dong-gu, Gwangju 501-759, South Korea.

出版信息

Endocr Relat Cancer. 2007 Jun;14(2):293-303. doi: 10.1677/ERC-06-0016.

Abstract

Acquired resistance to tamoxifen (TAM) is a serious therapeutic problem in breast cancer patients. The transition from chemotherapy-responsive breast cancer cells to chemotherapy-resistant cancer cells is mainly accompanied by the increased expression of multidrug resistance-associated proteins (MRPs). In this study, it was found that TAM-resistant MCF-7 (TAMR-MCF-7) cells expressed higher levels of MRP2 than control MCF-7 cells. Molecular analyses using MRP2 gene promoters supported the involvement of the pregnane X receptor (PXR) in MRP2 overexpression in TAMR-MCF-7 cells. Although CCAAT/enhancer-binding protein beta was overexpressed continuously in TAMR-MCF-7 cells, this might not be responsible for the transcriptional activation of the MRP2 gene. In addition, the basal activities of phosphatidylinositol 3-kinase (PI3-kinase) were higher in the TAMR-MCF-7 cells than in the control cells. The inhibition of PI3-kinase significantly reduced both the PXR activity and MRP2 expression in TAMR-MCF-7 cells. Overall, MRP2 induction plays a role in the additional acquisition of chemotherapy resistance in TAM-resistant breast cancer.

摘要

对他莫昔芬(TAM)产生获得性耐药是乳腺癌患者面临的一个严重治疗问题。化疗敏感的乳腺癌细胞向化疗耐药癌细胞的转变主要伴随着多药耐药相关蛋白(MRPs)表达的增加。在本研究中,发现耐TAM的MCF-7(TAMR-MCF-7)细胞中MRP2的表达水平高于对照MCF-7细胞。使用MRP2基因启动子的分子分析支持孕烷X受体(PXR)参与TAMR-MCF-7细胞中MRP2的过表达。尽管CCAAT/增强子结合蛋白β在TAMR-MCF-7细胞中持续过表达,但这可能不是MRP2基因转录激活的原因。此外,TAMR-MCF-7细胞中磷脂酰肌醇3-激酶(PI3-激酶)的基础活性高于对照细胞。抑制PI3-激酶可显著降低TAMR-MCF-7细胞中的PXR活性和MRP2表达。总体而言,MRP2的诱导在耐TAM的乳腺癌对化疗耐药的额外获得中起作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验